Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06594991 · ClinicalTrials.gov registry record · Phase 2
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
A Phase 2 study of Advanced Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 11
- Study locations
NCT06594991: Recruiting Phase 2 study of Advanced Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06594991 is a Phase 2 study of Advanced Melanoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 88 participants, below the 168-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (48% lower). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06594991, a Phase 2 study of Advanced Melanoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Primary Outcome
by RECIST v1.1
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Ipilimumab
- DRUG Fianlimab
Study Locations (11)
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Hackensack Meridian Health (Data Collection Only) - Hackensack
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University (Data Collection Only) - Stanford
Texas
- MD Anderson Cancer Center (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06594991 shows while recruiting
NCT06594991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 168-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Cemiplimab is the first listed.
NCT06594991 lists 11 locations in 4 states (New Jersey, New York, California).
Frequently Asked Questions
What is clinical trial NCT06594991 about?
NCT06594991 is a clinical study titled "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma". The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
What is the current status of trial NCT06594991?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2024-09-10. Estimated completion is 2027-09.
What conditions does trial NCT06594991 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06594991?
The interventions under investigation include: Cemiplimab (DRUG), Ipilimumab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT06594991?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06594991 being conducted?
This trial has 11 study locations across California, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06594991's enrollment target sits among peer trials
88 11th of 21 higher than 11 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RECRUITING · Phase 2
-
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI